BondTrue

COMING

SOON

 

BondTrue Receives Phase II Maryland Industrial Partnerships (MIPS) Award

 

Towson, Md., February 20, 2018—BondTrue LLC, a medical device company, announces the receipt of a Phase II Maryland Industrial Partnerships (MIPS) award from the Maryland Technology Enterprise Institute, a unit of the A. James Clark School of Engineering at the University of Maryland. The joint grant, worth $100,000, will be used for continuing development and research on the company’s patented device (#9,408,672), which aims to automate the process of surgical incisions and closures.

 

The MIPS program supports the development and commercialization of products and processes in Maryland through industry/university research partnerships. MIPS provides funds, matched by participating companies, to fund the research. 

 

After successfully completing Phase I, BondTrue plans to refine developed prototype designs, which will be used in research and testing.

 

The research will be conducted in the laboratory of Hugh Bruck, professor, director of graduate studies and associate chair of academic affairs in the department of mechanical engineering at the University of Maryland.

 

"The Phase II MIPS award will enable us to continue our momentum in the development of BondTrue for research and market introduction. We are excited about the progress we have made as a team with Hugh Bruck and his researchers,” said Dr. David Zachary Martin, co-founder and chief medical officer for BondTrue and a local plastic surgeon. "Using the newest technology, including state-of-the-art 3-D printers at the University of Maryland, has greatly advanced our prototype design, enabling us to accelerate the commercialization process.”

 

About BondTrue:

 

BondTrue is a device designed to automate the process of surgical incisions and closures. The goals of BondTrue are to:

 

  1. Completely standardize the beginning and ending portions of procedures that most operations have in common.

  2. Ensure a clean rapid incision.

  3. Perfectly align and evert skin closure, which will enhance post-operative healing and decrease post-operative infection rates by decreasing postoperative drainage and poor healing that can be attributed to beveled incisions or poorly aligned closures.

  4. Decrease wound closure time substantially, simultaneously decreasing time in the operating room and under anesthesia.

  5. Be utilized in telesurgery/robotics.

 

Millions of procedures are performed each year that could benefit from this technology, including but not limited to: total joint replacement, abdominal surgery, cardiac surgery, colectomy, breast surgery and spine surgery.

 

BondTrue is a privately held medical device design and development company.

 

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward looking statements within the meaning of the Private Securities Litigation Reform Act.  Forward-looking statements are typically identified by words or phrases such as "believe," "expect," "anticipate," "intend," "estimate, "assume," "plan," "outlook," "prospect," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions.  BondTrue cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  The following factors, among others, could cause actual results to differ materially from forward-looking statements or historical experience: risks relating to the early stage of product candidates under development; risks relating to BondTrue's ability to identify and enter into agreements with potential collaborative partners; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of BondTrue's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks). BondTrue's reports identify additional factors that can affect forward-looking statements.  These forward-looking statements speak only as of the date of this press release, and BondTrue assumes no duty to update forward-looking statements.

 

 

 

SOURCE  BondTrue, LLC

BondTrue.com

Aimee Martin

CEO

(301) 529-3787

 

BondTrue Receives Maryland Industrial Partnerships (MIPS) Award

 

Towson, Md., March 1, 2017—BondTrue LLC, a medical device company, announces the receipt of a Maryland Industrial Partnerships (MIPS) award from the Maryland Technology Enterprise Institute, a unit of the A. James Clark School of Engineering at the University of Maryland. The joint grant, worth $100,000, will be used for continuing research on the company’s patented device (#9,408,672), which automates the process of surgical incisions and closures.

 

The MIPS program supports the development and commercialization of products and processes in Maryland through industry/university research partnerships. MIPS provides matching funds, matched by participating companies, to pay for the university research.

 

Through the grant, BondTrue plans to design and develop an improved prototype, which will be used for multiple purposes, including animal trials, animation development and presentations.

 

The research will be conducted in the laboratory of Hugh Bruck, professor, director of graduate studies and associate chair of academic affairs in the department of mechanical engineering at the University of Maryland.

 

"We are very pleased with this award as it allows the continuation of important research on the BondTrue medical device," said Dr. David Zachary Martin, co-founder and chief medical officer for BondTrue and a local plastic surgeon. "This project will enable us to take the next step in commercializing the device. The MIPS program provides a great opportunity to advance collaborative projects in Maryland."

 

In standard operations performed today, surgical procedures begin and end in the same way: an incision is made with a scalpel; invasive procedure is performed; and the wound is brought together and hand-stitched with sutures or stapled together.

 

These advances, however, still require the surgeon to perform a clean and consistent incision and deliberately place each suture precisely to approximate the wound. This is done to the best of his or her ability with varying degrees of quality. Precision can be time-consuming. Poorly incised wounds and inadequately approximated wounds can result in delayed wound healing, poor

scarring, post-operative infections and higher healthcare costs.

 

BondTrue is a device designed to automate the process of surgical incisions and closures. BondTrue:

 

  1. Completely standardizes the beginning and ending portions of procedures that most operations have in common.

  2. Ensures a clean rapid incision.

  3. Perfectly aligns and everts skin closure, which will enhance post-operative healing and decrease post-operative infection rates by decreasing postoperative drainage and poor healing that can be attributed to beveled incisions or poorly aligned closures.

  4. Decreases wound closure time substantially, simultaneously decreasing time in the operating room and under anesthesia.

  5. May be utilized in telesurgery/robotics.

 

Millions of procedures are performed each year that could benefit from this Technology, including but not limited to: appendectomy, hysterectomy, total joint replacement, abdominal surgery, cardiac surgery, colectomy, breast surgery and spine surgery.

 

BondTrue is a privately-held medical device design and development company.

 

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward- looking statements within the meaning of the Private Securities Litigation Reform Act.  Forward-looking statements are typically identified by words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "assume," "plan," "outlook," "prospect," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions. BondTrue cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  The following factors, among others, could cause actual results to differ materially from forward-looking statements or historical experience: risks relating to the early stage of product candidates under development; risks relating to BondTrue's ability to identify and enter into agreements with potential collaborative partners; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of BondTrue proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks). BondTrue's reports identify additional factors that can affect forward-looking statements.  These forward-looking statements speak only as of the date of this press release, and BondTrue assumes no duty to update forward-looking statements.

 

 

SOURCE  BondTrue, LLC

BondTrue.com

Aimee Martin

CEO

(301) 529-3787

®

© 2019 by BondTrue, LLC